首页> 美国卫生研究院文献>Blood Advances >Fibrin and D-dimer bind to monomeric GPVI
【2h】

Fibrin and D-dimer bind to monomeric GPVI

机译:纤维蛋白和D-二聚体结合单体GPVI

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Fibrin has recently been shown to activate platelets through the immunoglobulin receptor glycoprotein VI (GPVI). In the present study, we show that spreading of human platelets on fibrin is abolished in patients deficient in GPVI, confirming that fibrin activates human platelets through the immunoglobulin receptor. Using a series of proteolytic fragments, we show that D-dimer, but not the E fragment of fibrin, binds to GPVI and that immobilized D-dimer induces platelet spreading through activation of Src and Syk tyrosine kinases. In contrast, when platelets are activated in suspension, soluble D-dimer inhibits platelet aggregation induced by fibrin and collagen, but not by a collagen-related peptide composed of a repeat GPO sequence or by thrombin. Using surface plasmon resonance, we demonstrate that fibrin binds selectively to monomeric GPVI with a KD of 302 nM, in contrast to collagen, which binds primarily to dimeric GPVI. These results establish GPVI as the major signaling receptor for fibrin in human platelets and provide evidence that fibrin binds to a distinct configuration of GPVI. This indicates that it may be possible to develop agents that selectively block the interaction of fibrin but not collagen with the immunoglobulin receptor. Such agents are required to establish whether selective targeting of either interaction has the potential to lead to development of an antithrombotic agent with a reduced effect on bleeding relative to current antiplatelet drugs.
机译:最近显示,血纤蛋白通过免疫球蛋白受体糖蛋白VI(GPVI)激活血小板。在本研究中,我们显示在GPVI缺乏的患者中,人血小板在血纤蛋白上的扩散被消除,这证实了血纤蛋白通过免疫球蛋白受体激活了人血小板。使用一系列蛋白水解片段,我们显示D-二聚体而不是血纤蛋白E片段与GPVI结合,并且固定的D-二聚体通过激活Src和Syk酪氨酸激酶诱导血小板扩散。相反,当血小板在悬浮液中被激活时,可溶性D-二聚体抑制由纤维蛋白和胶原蛋白诱导的血小板聚集,但不能抑制由重复GPO序列组成的胶原蛋白相关肽或凝血酶诱导的血小板聚集。使用表面等离振子共振,我们证明血纤蛋白选择性地与单体GPVI结合,其KD为302 nM,与胶原相反,胶原蛋白主要与二聚体GPVI结合。这些结果确立了GPVI作为人血小板中血纤蛋白的主要信号受体,并提供了血纤蛋白结合GPVI的独特构型的证据。这表明可能开发出选择性阻断血纤蛋白而不是胶原蛋白与免疫球蛋白受体相互作用的试剂。需要这样的试剂来确定相对于当前的抗血小板药物而言,选择性地靶向任一相互作用是否具有导致抗血栓形成剂发展的潜力,并且对出血的作用降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号